Avadel Pharmaceuticals Plc Sponsored ADR AVDL 深 沪

Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal

Avadel reviews Lundbeck's unsolicited $23 offer while maintaining its agreement with Alkermes as its board evaluates whether the new proposal could be superior.

11-15 00:37

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Avadel Pharmaceuticals granted stock options to two new employees and its new Chief Operating Officer, Susan Rodriguez, under its 2021 Inducement Plan. The options, totaling 309,600 shares, vest over four years and have a ten-year term. The grants comply with Nasdaq Listing Rule 5635(c)(4).

06-16 20:05

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Avadel’s LUMRYZ granted Orphan Drug Designation for treating Idiopathic Hypersomnia, offering once-nightly dosing. Phase 3 trial ongoing, aims to improve patient care for rare sleep disorder.

06-05 11:30

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025

05-29 20:05

Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Avadel Pharmaceuticals announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025. A live webcast and archived recording will be available on the company's Investor Relations website for 90 days. The company focuses on innovative solutions for medications, with its product LUMRYZ™ approved for narcolepsy treatment. Investor and media contacts are provided.

05-29 12:00

Avadel Pharmaceuticals Announces Publication Of Data In 'Sleep Medicine' Highlighting Efficacy Of LUMRYZ Extended-Release Oral Suspension In Improving Narcolepsy Symptoms Regardless Of Concomitant Use Of An Alerting Agent

– Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and were not using a stable dose of an alerting agent – – Baseline data underscore that alerting

2024-09-25 20:10

Avadel Pharmaceuticals Announces Publication Of RESTORE Data Highlighting Challenges With Twice-Nightly Oxybates And Strong Patient Preference For Once-Nightly LUMRYZ Dosing Extended-Release Oral Suspension

– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens –   – 91% reported being better able to sleep through the night after switching to LUMRYZ – – 93% of those who switched to LUMRYZ would recommend it to family or frie...

2024-09-03 20:21

HC Wainwright & Co. Reiterates Buy on Avadel Pharmaceuticals, Maintains $27 Price Target

HC Wainwright & Co. analyst Oren Livnat reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $27 price target.

2024-08-29 01:25

Avadel Pharma Shares Fall After Split Decision in Legal Fight Over Narcolepsy Drug

01:01 PM EDT, 08/28/2024 (MT Newswires) -- Avadel Pharmaceuticals (AVDL) shares declined Wednesday after scoring a partial victory in a legal fight with Jazz Pharmaceuticals (JAZZ) over Avadel's bid to commercialize its Lumryz medication for the treatment of excessive daytime sleepiness in adults wi...

2024-08-29 01:01

Avadel Pharmaceuticals Announces Publication In Clinical Therapeutics Of Data Highlighting Weight Loss In People With Narcolepsy Treated With LUMRYZ Extended-Release Oral Suspension

Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of results of a post-hoc analysis from the completed pivotal Phase 3 REST-ON clinical trial demonstrating greater weight loss in patients who re...

2024-08-20 20:02